Mandate

Vinge advises Intrum in connection with its EUR 450m bond issuance

Vinge advises Intrum AB (publ) in connection with its issuance of senior secured fixed rate bonds in an amount of EUR 450 million.

The proceeds will be used to refinance, in part, Intrum’s 3.125% Senior Notes due 2024, and the bonds will be listed on the Securities Official List of the Luxembourg Stock Exchange. The bonds have a tenor of five years and were issued with a coupon of 9.25 per cent and at a price of 97.020% of the nominal amount.

Vinge’s team consisted of Louise Brorsson Salomon, Lionardo Ojeda, Jolinn Uhlin, Calle Tengwall Pagels (Banking and Finance), Victor Ericsson and Maja Prahl (Tax)

Related

Vinge has advised Egetis Therapeutics in connection with a directed share issue

Vinge has advised Egetis Therapeutics AB (publ) (“Egetis Therapeutics”), listed on Nasdaq Stockholm, in connection with a directed share issue whereby Egetis Therapeutics raised proceeds of approximately SEK 183 million before transaction costs.
October 06, 2025

Vinge worked with funds advised by Agilitas on the buy-out of Vivicta (previously Tietoevry Tech Services), including on the issuance of senior secured bonds and on entering into a super senior RCF

Vinge, together with O’Melveny as lead counsel and Avance, worked with funds advised by Agilitas Private Equity LLP (“Agilitas”), the pan-European mid-market private equity firm, in their backing of Vivicta. The buy-out was previously announced on 24 March 2025 and closed on 2 September 2025.
October 03, 2025

Vinge has advised Hansa Biopharma in connection with a directed share issue of approx. SEK 671.5 million

Vinge has advised Hansa Biopharma AB (publ) in connection with a directed share issue through which the company raises proceeds of approx. SEK 671.5 million before transaction costs.
October 03, 2025